Background The purpose of this study was to evaluate the effects of cytoreductive
nephrectomy (CN) and metastasectomies on the survival of patients with synchronous …

Objectives To explore the real-world data regarding survival following metastasectomy (MS)
for renal cell carcinoma (RCC) in the postcytokine therapy era. Patients and Methods …

Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma
(mRCC) is not well characterized and varies due to the lack of robust data to guide treatment …

In Switzerland efficient availability of novel drugs for renal cell cancer (RCC) has been
granted early. Since the advent of the targeted agents for RCC the usage of these drugs has …

Abstract Background The International mRCC (metastatic renal cell carcinoma) Database
Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the …

Background/Aim: We performed a retrospective survey on our metastatic renal cell
carcinoma (MRCC) patients who had received targeted therapies, and afterwards evaluated …

Background Treatment paradigms for management of metastatic renal cell carcinoma
(mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in …

Conclusion Whatever the modest progress made for a small number of patients with MRCC,
the majority of patients will die within 5 years of diagnosis of MRCC. Therefore, there is a …

Background With the advent of small-molecule “targeted” therapies, the prevailing treatment
paradigm for metastatic renal cell carcinoma (mRCC) is that all patients who are able to …

Introduction: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly
introduced to market, comparative randomized trial evidence guiding treatment decisions is …